Genome Center to help detect nCoV via whole-genome sequencing

The Centers for Disease Control and Prevention (CDC) describes whole-genome sequencing as a “laboratory procedure that determines the order of bases in the genome of an organism in one process.”

According to CDC, scientists conduct data analysis, which is the fourth step of whole-genome sequencing, to compare “bacterial sequences and identify differences.”

Philippine Genome Center gears up to verify presence of 2019-nCoV through whole genome sequencing

With the use of Next Generation DNA/RNA Sequencing equipment (NGS) available at the Philippine Genome Center (PGC) in the University of the Philippines Diliman Campus, the team of the DNA Sequencing Core Facility (DSCF) is ready and willing to assist RITM and the DOH in confirming suspected cases of 2019-Novel Coronavirus (2019-nCoV) in the country.

PGC researchers attend annual Human Genetics Meeting

Mr. Garrido and Ms. Alcantara shared the preliminary findings of the two Philippine Genome Center’s projects, “Mutational analysis of KRAS, NRAS, PIK3CA, BRAF, and PTEN genes in Filipino Colorectal Cancer Patients,” and “Detection and Functionalization of KRAS, NRAS, PIK3CA, BRAF, and PTEN Gene Mutations in Filipino Colorectal Cancer Patients,” through poster presentations.

Read more about Dr. Raul Destura’s projects in NIMBB-UP Manila

NIMBB UP-NIH Projects Improving Molecular Diagnosis of Drug Resistant Tuberculosis (2016) Funding: US-NIH (RO1) Role: Principal Investigator Collaborators: University of California San Francisco Status: On-going Project 3D Targets: The UK-Philippine Research Consortium for Dengue Diagnostics and Drug Targets (2015) Funding: MRC-Newton Fund – PCHRD Role: Principal Investigator Collaborators: University of Glasgow and University of Bristol […]

reynaldo_garcia

Reynaldo L. Garcia, PhD

Dr. Garcia did postdoctoral work in New Zealand (University of Otago Medical School), Paris (Hopital de la Pitie-Salpetriere/Universite Pierre et Marie Curie), the United States (Case Western Reserve University School of Medicine) and London (University College London), before being appointed senior research scientist at Cancer Research UK’s Beatson Institute in Scotland. He has worked on Merck- and Roche-funded projects involving characterization of drug targets for pain and development of drug screening assays for disrupting cellular proliferation in cancer, respectively.